Key result
Percutaneous transluminal septal myocardial ablation significantly reduced the mean resting left ventricular outflow tract pressure gradient from 70 to 24 mmHg (p<0.0001) in patients with HOCM.
Why the study?
Does percutaneous transluminal septal myocardial ablation improve hemodynamics and symptoms in medically refractory patients with hypertrophic obstructive cardiomyopathy?
Population
27 medically refractory patients with hypertrophic obstructive cardiomyopathy (HOCM)
Design
Case_series
Follow-up
mean 2.2+/-1.7 years
Authors
Loading...
PTSMA-associated gradient reduction in HOCM supports further study; leaves open randomized confirmation of clinical outcomes.
Observational (n=27)
Does percutaneous transluminal septal myocardial ablation improve hemodynamics and symptoms in medically refractory patients with hypertrophic obstructive cardiomyopathy?
p-value: p=<0.0001
PTSMA is a safe and effective procedure that significantly reduces left ventricular outflow tract gradients and improves symptoms in patients with medically refractory hypertrophic obstructive cardiomyopathy.
Tsuchikane et al. (2003) conducted an observational in Hypertrophic obstructive cardiomyopathy (HOCM) (n=27). Percutaneous transluminal septal myocardial ablation (PTSMA) vs. Baseline was evaluated on Mean resting left ventricular outflow tract pressure gradient (PG) (p=<0.0001). Percutaneous transluminal septal myocardial ablation significantly reduced the mean resting left ventricular outflow tract pressure gradient from 70 to 24 mmHg (p<0.0001) in patients with HOCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: